Of them, kallikrein 3 (hK3), or more commonly named as prostate-specific antigen (PSA), has gained prominence as the most valuable tumour marker and is currently used widely for the diagnosis, monitoring, and population screening for prostate cancer (Catalona et al, 1991; Mettlin et al, 1993). This evidence concerns the gene KLK3 and neoplasm.